Clinical practice guidelines for the treatment of Ewing sarcoma (Spanish Sarcoma Research Group-GEIS).
EWSR1
Ewing sarcoma
Malignant bone tumours
Small round cell sarcomas
“Ewing like” sarcoma
Journal
Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
ISSN: 1699-3055
Titre abrégé: Clin Transl Oncol
Pays: Italy
ID NLM: 101247119
Informations de publication
Date de publication:
19 Aug 2024
19 Aug 2024
Historique:
received:
26
03
2024
accepted:
03
07
2024
medline:
19
8
2024
pubmed:
19
8
2024
entrez:
19
8
2024
Statut:
aheadofprint
Résumé
Ewing sarcoma is a small round-cell sarcoma characterized by gene fusion involving EWSR1 (or another TET family protein like FUS) and an ETS family transcription factor. The estimated incidence of this rare bone tumor, which occurs most frequently in adolescents and young adults, is 0.3 per 100,000/year. Although only 25% of patients with Ewing sarcoma are diagnosed with metastatic disease, historical series show that this is a systemic disease. Patient management requires multimodal therapies-including intensive chemotherapy-in addition to local treatments (surgery and/or radiotherapy). In the recurrent/refractory disease setting, different approaches involving systemic treatments and local therapies are also recommended as well as patient inclusion in clinical trials whenever possible. Because of the complexity of Ewing sarcoma diagnosis and treatment, it should be carried out in specialized centers and treatment plans should be designed upfront by a multidisciplinary tumor board. These guidelines provide recommendations for diagnosis, staging, and multimodal treatment of Ewing sarcoma.
Identifiants
pubmed: 39158802
doi: 10.1007/s12094-024-03602-5
pii: 10.1007/s12094-024-03602-5
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s).
Références
https://www.nccn.org/professionals/physician_gls/pdf/bone.pdf . Accessed 20 Mar 2021.
Casali PG, Bielack S, Abecassis N, Aro HT, Bauer S, Biagini R, et al. Bone sarcomas: ESMO- PaedCan-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29(Suppl):iv79–95.
doi: 10.1093/annonc/mdy310
pubmed: 30285218
Dykewicz CA. Summary of the guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. Clin Infect Dis. 2001;33(2):139–44.
doi: 10.1086/321805
pubmed: 11418871
Stiller CA, Trama A, Serraino D, Rossi S, Navarro C, Chirlaque MD, Casali PG. Descriptive epidemiology of sarcomas in Europe: report from the RARECARE project. Eur J Cancer. 2013;49(3):684–95. https://doi.org/10.1016/j.ejca.2012.09.011 . (Epub 2012 Oct 15. PMID: 23079473).
doi: 10.1016/j.ejca.2012.09.011
pubmed: 23079473
Panicek DM, Gatsonis C, Rosenthal DI, Seeger LL, Huvos AG, Moore SG, Caudry DJ, Palmer WE, McNeil BJ. CT and MR imaging in the local staging of primary malignant musculoskeletal neoplasms: report of the Radiology Diagnostic Oncology Group. Radiology. 1997;202(1):237–46. https://doi.org/10.1148/radiology.202.1.8988217 . (PMID: 8988217).
doi: 10.1148/radiology.202.1.8988217
pubmed: 8988217
Clemente EJI, Navarro OM, Navallas M, Ladera E, Torner F, Sunol M, Garraus M, March JC, Barber I. Multiparametric MRI evaluation of bone sarcomas in children. Insights Imaging. 2022;13(1):1–18. https://doi.org/10.1186/s13244-022-01177-9 .
doi: 10.1186/s13244-022-01177-9
Kubo T, Furuta T, Johan MP, Sakuda T, Ochi M, Adachi N. A meta-analysis supports core needle biopsy by radiologists for better histological diagnosis in soft tissue and bone sarcomas. Medicine (United States). 2018. https://doi.org/10.1097/MD.0000000000011567 .
doi: 10.1097/MD.0000000000011567
pmcid: 6309347
Guimarães JB, Rigo L, Lewin F, Emerick A. The importance of PET/CT in the evaluation of patients with Ewing tumors. Radiol Bras. 2015;48(3):175–80. https://doi.org/10.1590/0100-3984.2013.1887 . (PMID: 26185344; PMCID: PMC4492570).
doi: 10.1590/0100-3984.2013.1887
pubmed: 26185344
pmcid: 4492570
Liu PT, Valadez SD, Chivers FS, Roberts CC, Beauchamp CP. Anatomically based guidelines for core needle biopsy of bone tumors: implications for limb-sparing surgery. Radiographics. 2007;27:189–206.
doi: 10.1148/rg.271065092
pubmed: 17235007
Grünewald TGP, Cidre-Aranaz F, Surdez D, Tomazou EM, de Álava E, Kovar H, Sorensen PH, Delattre O, Dirksen U. Ewing sarcoma. Nat Rev Dis Primers. 2018;4(1):5. https://doi.org/10.1038/s41572-018-0003-x . (PMID: 29977059).
doi: 10.1038/s41572-018-0003-x
pubmed: 29977059
Llombart-Bosch A, Machado I, Navarro S, Bertoni F, Bacchini P, Alberghini M, Karzeladze A, Savelov N, Petrov S, Alvarado-Cabrero I, Mihaila D, Terrier P, Lopez-Guerrero JA, Picci P. Histological heterogeneity of Ewing’s sarcoma/PNET: an immunohistochemical analysis of 415 genetically confirmed cases with clinical support. Virchows Arch. 2009;455(5):397–411. https://doi.org/10.1007/s00428-009-0842-7 . (Epub 2009 Oct 17 PMID: 19841938).
doi: 10.1007/s00428-009-0842-7
pubmed: 19841938
Machado I, Noguera R, Mateos EA, Calabuig-Fariñas S, López FI, Martínez A, Navarro S, Llombart-Bosch A. The many faces of atypical Ewing’s sarcoma. A true entity mimicking sarcomas, carcinomas and lymphomas. Virchows Arch. 2011;458(3):281 (90 Koch R10.1007/s00428-010-1023-4. Epub 2010 Dec 23. PMID: 21181413).
doi: 10.1007/s00428-010-1023-4
pubmed: 21181413
Machado I, Yoshida A, Morales MGN, Abrahão-Machado LF, Navarro S, Cruz J, Lavernia J, Parafioriti A, Picci P, Llombart-Bosch A. Review with novel markers facilitates precise categorization of 41 cases of diagnostically challenging, “undifferentiated small round cell tumours”. A clinicopathologic, immunophenotypic and molecular analysis. Ann Diagn Pathol. 2018;34:1–12. https://doi.org/10.1016/j.anndiagpath.2017.11.011 .
doi: 10.1016/j.anndiagpath.2017.11.011
pubmed: 29661713
Wang WL, Patel NR, Caragea M, Hogendoorn PC, López-Terrada D, Hornick JL, Lazar AJ. Expression of ERG, an Ets family transcription factor, identifies ERG-rearranged Ewing sarcoma. Mod Pathol. 2012;25(10):1378–83. https://doi.org/10.1038/modpathol.2012.97 . (Epub 2012 Jul 6 PMID: 22766791).
doi: 10.1038/modpathol.2012.97
pubmed: 22766791
Bishop JA, Alaggio R, Zhang L, Seethala RR, Antonescu CR. Adamantinoma-like Ewing family tumors of the head and neck: a pitfall in the differential diagnosis of basaloid and myoepithelial carcinomas. Am J Surg Pathol. 2015;39(9):1267–74. https://doi.org/10.1097/PAS.0000000000000460 . (PMID:26034869;PMCID:PMC4537687).
doi: 10.1097/PAS.0000000000000460
pubmed: 26034869
pmcid: 4537687
Casali PG, Bielack S, Abecassis N, Aro HT, Bauer S, Biagini R, et al. Bone sarcomas: ESMO- PaedCan-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29(Suppl 4):iv79–95.
doi: 10.1093/annonc/mdy310
pubmed: 30285218
Treglia G, Salsano M, Stefanelli A, Mattoli MV, Giordano A, Bonomo L. Diagnostic accuracy of
doi: 10.1007/s00256-011-1298-9
pubmed: 22072239
Kalus S, Saifuddin A. Whole-body MRI vs bone scintigraphy in the staging of Ewing sarcoma of bone: a 12-year single-institution review. Eur Radiol. 2019;29(10):5700–8. https://doi.org/10.1007/s00330-019-06132-9 . (Epub 2019 Mar 26 PMID: 30915559).
doi: 10.1007/s00330-019-06132-9
pubmed: 30915559
Cesari M, Righi A, Colangeli M, Gambarotti M, Spinnato P, Ferraro A, et al. Bone marrow biopsy in the initial staging of Ewing sarcoma: experience from a single institution. Pediatr Blood Cancer. 2019;66(6):e27653. https://doi.org/10.1002/pbc.27653 . (Epub 2019 Feb 5. PMID: 30724024).
doi: 10.1002/pbc.27653
pubmed: 30724024
R.G. TNM staging of tumors of bone. PathologyOutlines.com website. http://www.pathologyoutlines.com/topic/bonestaging.html . Accessed 24 Feb 2022.
Cotterill SJ, Ahrens S, Paulussen M, Jürgens HF, Voûte PA, Gadner H, Craft AW. Prognostic factors in Ewing’s tumor of bone: analysis of 975 patients from the European Intergroup Cooperative Ewing’s Sarcoma Study Group. J Clin Oncol. 2000;18(17):3108–14. https://doi.org/10.1200/JCO.2000.18.17.3108 . (PMID: 10963639).
doi: 10.1200/JCO.2000.18.17.3108
pubmed: 10963639
Bacci G, Longhi A, Ferrari S, Mercuri M, Versari M, Bertoni F. Prognostic factors in non- metastatic Ewing’s sarcoma tumor of bone: an analysis of 579 patients treated at a single institution with adjuvant or neoadjuvant chemotherapy between 1972 and 1998. Acta Oncol. 2006;45(4):469–75.
doi: 10.1080/02841860500519760
pubmed: 16760184
Bosma SE, Lancia C, Rueten-Budde AJ, et al. Easy-to-use clinical tool for survival estimation in Ewing sarcoma at diagnosis and after surgery. Sci Rep. 2019;9(1):11000.
doi: 10.1038/s41598-019-46721-8
pubmed: 31358784
pmcid: 6662666
Salzer-Kuntschik M, Brand G, Delling G. Determination of the degree of morphological regression following chemotherapy in malignant bone tumors. Pathologe. 1983;4(3):135–41.
pubmed: 6576329
Li S, Yang Q, Wang H, et al. Prognostic significance of serum lactate dehydrogenase levels in Ewing’s sarcoma: a meta-analysis. Mol Clin Oncol. 2016;5(6):832–8.
doi: 10.3892/mco.2016.1066
pubmed: 28105365
pmcid: 5228491
Anderton J, Moroz V, Marec-Berard P, et al. International randomised controlled trial for the treatment of newly diagnosed EWING sarcoma family of tumours—EURO EWING 2012 Protocol. Trials. 2020;21(1):96.
doi: 10.1186/s13063-019-4026-8
pubmed: 31952545
pmcid: 6969439
Friedman DN, Chastain K, Chou JF, Moskowitz CS, Adsuar R, Wexler LH, Chou AJ, DeRosa A, Candela J, Magnan H, Pun S, Kahan T, Wolden SL, Meyers PA, Oeffinger KC. Morbidity and mortality after treatment of Ewing sarcoma: A single-institution experience. Pediatr Blood Cancer. 2017 Nov;64(11). https://doi.org/10.1002/pbc.26562 . Epub 2017 Apr 18. PMID: 28417551
Womer RB, West DC, Krailo MD, et al. Randomized controlled trial of interval compressed chemotherapy for the treatment of localized Ewing sarcoma: a report from the Children´s Oncology Group. J Clin Oncol. 2012;30:4148–54.
doi: 10.1200/JCO.2011.41.5703
pubmed: 23091096
pmcid: 3494838
Brennan B, Kirton L, Marec-Bérard P, Gaspar N, Laurence V, Martín-Broto J, Sastre A, Gelderblom H, Owens C, Fenwick N, Strauss S, Moroz V, Whelan J, Wheatley K. Comparison of two chemotherapy regimens in patients with newly diagnosed Ewing sarcoma (EE2012): an open-label, randomised, phase 3 trial. Lancet. 2022;400(10362):1513–21. https://doi.org/10.1016/S0140-6736(22)01790-1 . (PMID: 36522207).
doi: 10.1016/S0140-6736(22)01790-1
pubmed: 36522207
Ferrari S, Sundby Hall K, Luksch R, et al. Nonmetastatic Ewing family tumors. High dose chemotherapy with stem cell rescue in poor responder patients. Results of the Italian Sarcoma Group/Scandinavian Sarcoma Group III protocol. Ann Oncol. 2011;22:1221–7.
doi: 10.1093/annonc/mdq573
pubmed: 21059639
Whelan J, Le Deley MC, Dirksen U, Le Teuff G, Brennan B, Gaspar N, Hawkins DS, Amler S, Bauer S, Bielack S, Blay JY, Burdach S, Castex MP, Dilloo D, Eggert A, Gelderblom H, Gentet JC, Hartmann W, Hassenpflug WA, Hjorth L, Jimenez M, Klingebiel T, Kontny U, Kruseova J, Ladenstein R, Laurence V, Lervat C, Marec-Berard P, Marreaud S, Michon J, Morland B, Paulussen M, Ranft A, Reichardt P, van den Berg H, Wheatley K, Judson I, Lewis I, Craft A, Juergens H, Oberlin O; Euro-E.W.I.N.G.99 and EWING-2008 Investigators. High-Dose Chemotherapy and Blood Autologous Stem-Cell Rescue Compared With Standard Chemotherapy in Localized High-Risk Ewing Sarcoma: Results of Euro-E.W.I.N.G.99 and Ewing-2008. J Clin Oncol. 2018;36(31):JCO2018782516. https://doi.org/10.1200/JCO.2018.78.2516 . Epub ahead of print. PMID: 30188789; PMCID: PMC6209090.
Dirksen U, Brennan B, Le Deley MC, Cozic N, van den Berg H, Bhadri V, Euro-E.W.I.N.G. 99andEwing2008Investigators, et al. High-Dose Chemotherapy Compared With Standard Chemotherapy and Lung Radiation in Ewing Sarcoma With Pulmonary Metastases: Results of the European Ewing Tumour Working Initiative of National Groups, 99 Trial and EWING 2008. J Clin Oncol. 2019;37(34):3192–202. https://doi.org/10.1200/JCO.19.00915 . (Epub 2019 Sep 25. PMID: 31553693; PMCID: PMC6881099).
doi: 10.1200/JCO.19.00915
pubmed: 31553693
pmcid: 6881099
Koch R, Gelderblom H, Haveman L, et al. High dose treosulfan and melphalan as consolidation therapy versus standard therapy for high risk (metastatic)Ewing sarcoma. J Clin Oncol. 2022;40:2307.
doi: 10.1200/JCO.21.01942
pubmed: 35427190
Ahmed SK, Robinson SI, Okuno SH, et al. Adult Ewing sarcoma: survival and local control outcomes in 36 patients with metastatic disease. Am J Clin Oncol. 2014;37:423.
doi: 10.1097/COC.0b013e31827de65e
pubmed: 23388557
Bacci G, Baladelli A, Forni C, et al. Adjuvant and neoadjuvant chemotherapy for Ewing sarcoma family tumors in patients between 40 and 60: report of 35 cases and comparison of results with 586 younger patients treated with the same protocols in the same years. Cancer. 2007;109:780.
doi: 10.1002/cncr.22456
pubmed: 17219445
Pretz JL, Baryasuskas CM, George S, et al. Localized adult Ewing sarcoma: favourable outcomes with alternating vincristine, doxorubicin, cyclophosphamide, and ifosfamide, etoposide (VDC/IE)-based multimodality therapy. Oncologists. 2017;22:1265.
doi: 10.1634/theoncologist.2016-0463
McCarville MB, Federico SM, Bishop MW, Pappo AS, Shulkin BL. Assessment of chemotherapy response in Ewing sarcoma. Radiology. 2016;281(2):647–8.
doi: 10.1148/radiol.2016160903
pubmed: 27755931
Raciborska A, Bilska K, Drabko K, Michalak E, Chaber R, Pogorzała M, Połczyńska K, Sobol G, Wieczorek M, Muszyńska-Rosłan K, Rychlowska-Pruszyńska M, Rodriguez-Galindo C, Dziuk M. Response to chemotherapy estimates by FDG PET is an important prognostic factor in patients with Ewing sarcoma. Clin Transl Oncol. 2016;18(2):189–95. https://doi.org/10.1007/s12094-015-1351-6 . (Epub 2015 Aug 7 PMID: 26250765).
doi: 10.1007/s12094-015-1351-6
pubmed: 26250765
Palmerini E, Colangeli M, Nanni C, Fanti S, Marchesi E, Paioli A, et al. The role of FDG PET/CT in patients treated with neoadjuvant chemotherapy for localized bone sarcomas. Eur J Nucl Med Mol Imaging. 2017;44(2):215–23.
doi: 10.1007/s00259-016-3509-z
pubmed: 27645694
Hyun OJ, Luber BS, Leal JP, Wang H, Bolejack V, Schuetze SM, Schwartz LH, Helman LJ, Reinke D, Baker LH, Wahl RL. Response to early treatment evaluated with 18F-FDG PET and PERCIST 1.0 predicts survival in patients with Ewing sarcoma family of tumors treated with a monoclonal antibody to the insulin like growth factor 1 receptor. J Nucl Med. 2016;57(5):735–40. https://doi.org/10.2967/jnumed.115.162412 . (Epub 2016 Jan 21. PMID: 26795289; PMCID: PMC5548359).
doi: 10.2967/jnumed.115.162412
Asmar K, Saade C, Salman R, et al. The value of diffusion weighted imaging and apparent diffusion coefficient in primary Osteogenic and Ewing sarcomas for the monitoring of response to treatment: Initial experience. European Journal of Radiology. 2020;124:108855. https://doi.org/10.1016/j.ejrad.2020.108855 . PMID: 32018075
Wardelmann E, Haas RL, Bovée JV, et al. Evaluation of response after neoadjuvant treatment in soft tissue sarcomas; the European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC-STBSG) recommendations for pathological examination and reporting. Eur J Cancer. 2016;53:84–95.
doi: 10.1016/j.ejca.2015.09.021
pubmed: 26700077
Schuck A, Ahrens S, Paulussen M, et al. Local therapy in localized Ewing tumors: results of 1058 patients treated in the CESS 81, CESS 86, and EICESS 92 trials. Int J Radiat Oncol Biol Phys. 2003;55:168–77.
doi: 10.1016/S0360-3016(02)03797-5
pubmed: 12504050
Schuck A, Ahrens S, Paulussen M, Kuhlen M, Könemann S, Rübe C, Winkelmann W, Kotz R, Dunst J, Willich N, Jürgens H. Local therapy in localized Ewing tumors: results of 1058 patients treated in the CESS 81, CESS 86, and EICESS 92 trials. Int J Radiat Oncol Biol Phys. 2003. https://doi.org/10.1016/S0360-3016(02)03797-5 .
doi: 10.1016/S0360-3016(02)03797-5
pubmed: 12873688
Casali PG, Bielack S, Abecassis N, Aro HT, Bauer S, Biagini R, Bonvalot S, Boukovinas I, Bovee JVMG, Brennan B, Brodowicz T, Broto JM, Brugières L, Buonadonna A, De Álava E, Dei Tos AP, Del Muro XG, Dileo P, Dhooge C, Eriksson M, Fagioli F, Fedenko A, Ferraresi V, Ferrari A, Ferrari S, Frezza AM, Gaspar N, Gasperoni S, Gelderblom H, Gil T, Grignani G, Gronchi A, Haas RL, Hassan B, Hecker-Nolting S, Hohenberger P, Issels R, Joensuu H, Jones RL, Judson I, Jutte P, Kaal S, Kager L, Kasper B, Kopeckova K, Krákorová DA, Ladenstein R, Le Cesne A, Lugowska I, Merimsky O, Montemurro M, Morland B, Pantaleo MA, Piana R, Picci P, Piperno-Neumann S, Pousa AL, Reichardt P, Robinson MH, Rutkowski P, Safwat AA, Schöffski P, Sleijfer S, Stacchiotti S, Strauss SJ, Sundby Hall K, Unk M, Van Coevorden F, van der Graaf WTA, Whelan J, Wardelmann E, Zaikova O, Blay JY, ESMO Guidelines Committee, PaedCan and ERN EURACAN. Bone sarcomas: ESMO-PaedCan-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29(Suppl 4):iv9–95. https://doi.org/10.1093/annonc/mdy310 . (PMID: 30285218).
doi: 10.1093/annonc/mdy310
Sluga M, Windhager R, Lang S, Heinzl H, Krepler P, Mittermayer F, Dominkus M, Zoubek A, Kotz R. The role of surgery and resection margins in the treatment of Ewing’s sarcoma. Clin Orthop Relat Res. 2001;392:394–9.
doi: 10.1097/00003086-200111000-00051
Alvarez-SanNicolas J, Gracia-Alegria I, Trullols-Tarrago L, et al. Prognostic factors and survival in Ewing’s sarcoma treated by limb salvage surgery. Clin Transl Oncol. 2019;21:1374–82.
doi: 10.1007/s12094-019-02067-1
pubmed: 30798513
Miller BJ, Gao Y, Duchman KR. Does surgery or radiation provide the best overall survival in Ewing’s sarcoma? A review of the National Cancer Data Base. J Surg Oncol. 2017;116(3):384–90. https://doi.org/10.1002/jso.24652 . (Epub 2017 Apr 18 PMID: 28420037).
doi: 10.1002/jso.24652
pubmed: 28420037
Yamazaki T, McLoughlin GS, Patel S, Rhines LD, Fourney DR. Feasibility and safety of en bloc resection for primary spine tumors: a systematic review by the Spine Oncology Study Group. Spine (Phila Pa 1976). 2009;34(22 Suppl):S31–8. https://doi.org/10.1097/BRS.0b013e3181b8b796 .
doi: 10.1097/BRS.0b013e3181b8b796
pubmed: 19829275
Boriani S, Weinstein JN, Biagini R. Primary bone tumors of the spine. Terminology and surgical staging. Spine. 1997;22:1036–44.
doi: 10.1097/00007632-199705010-00020
pubmed: 9152458
Donaldson SS. Ewing sarcoma: radiation dose and target volume. Pediatr Blood Cancer. 2004;42(5):471–6. https://doi.org/10.1002/pbc.10472 . (PMID: 15049023).
doi: 10.1002/pbc.10472
pubmed: 15049023
Schuck A, Rübe C, Könemann S, Rübe CE, Ahrens S, Paulussen M, Dunst J, Jürgens H, Willich N. Postoperative radiotherapy in the treatment of Ewing tumors: Influence of the interval between surgery and radiotherapy. Strahlenther Onkol. 2002. https://doi.org/10.1007/s00066-002-0883-1 .
doi: 10.1007/s00066-002-0883-1
pubmed: 12491060
Haeusler J, Ranft A, Boelling T, Gosheger G, Braun-Munzinger G, Vieth V, Burdach S, vanden Berg H, Juergens H, Dirksen U. The value of local treatment in patients with primary, disseminated, multifocal Ewing sarcoma (PDMES). Cancer. 2010;116(2):443–50.
doi: 10.1002/cncr.24740
pubmed: 19924786
Granowetter L, Womer R, Devidas M, Krailo M, Wang C, Bernstein M, Marina N, Leavey P, Gebhardt M, Healey J, Shamberger RC, Goorin A, Miser J, Meyer J, Arndt CA, Sailer S, Marcus K, Perlman E, Dickman P, Grier HE. Dose-intensified compared with standard chemotherapy for nonmetastatic Ewing sarcoma family of tumors: a Children’s Oncology Group Study. J Clin Oncol. 2009;27(15):2536–41. https://doi.org/10.1200/JCO.2008.19.1478 . (Epub 2009 Apr 6. PMID: 19349548; PMCID: PMC2684856).
doi: 10.1200/JCO.2008.19.1478
pubmed: 19349548
pmcid: 2684856
Meyers PA, Krailo MD, Ladanyi M, Chan KW, Sailer SL, Dickman PS, et al. High-dose melphalan, etoposide, total-body irradiation, and autologous stem-cell reconstitution as consolidation therapy for high-risk Ewing’s sarcoma does not improve prognosis. J Clin Oncol. 2001;19(11):2812–20. https://doi.org/10.1200/JCO.2001.19.11.2812 . (PMID: 11387352).
doi: 10.1200/JCO.2001.19.11.2812
pubmed: 11387352
Reza J, Sammann A, Jin C, Horvai A, Hudnall M, Jablons DM, Jahan T, Kornak J, Mann MJ. Aggressive and minimally invasive surgery for pulmonary metastasis of sarcoma. J Thorac Cardiovasc Surg. 2014;147(4):1193–200. https://doi.org/10.1016/j.jtcvs.2013.12.021 . (Epub 2014 Jan 2 PMID: 24507991).
doi: 10.1016/j.jtcvs.2013.12.021
pubmed: 24507991
Letourneau PA, Shackett B, Xiao L, Trent J, Tsao KJ, Lally K, Hayes-Jordan A. Resection of pulmonary metastases in pediatric patients with Ewing sarcoma improves survival. J Pediatr Surg. 2011;46(2):332–5.
doi: 10.1016/j.jpedsurg.2010.11.013
pubmed: 21292083
pmcid: 3097027
Brown Lindsay C., Rachael A. Lester, Michael P. Grams, Michael G. Haddock, Kenneth R. Olivier, Carola A. S. Arndt, Peter S Rose, Nadia N Issa Laack. Stereotactic Body Radiotherapy for Metastatic and Recurrent Ewing Sarcoma and Osteosarcoma. Sarcoma. 2014;2014. https://api.semanticscholar.org/CorpusID:15216102
Baumann BC, Nagda SN, Kolker JD, et al. Efficacy and safety of stereotactic body radiation therapy for the treatment of pulmonary metastases from sarcoma: a potential alternative to resection. J Surg Oncol. 2016;114:65–9.
doi: 10.1002/jso.24268
pubmed: 27111504
Bölling T, Schuck A, Paulussen M, Dirksen U, Ranft A, Könemann S, Dunst J, Willich N, Jürgens H. Whole lung irradiation in patients with exclusively pulmonary metastases of Ewing tumors Toxicity analysis and treatment results of the EICESS-92 trial. Strahlenther Onkol. 2008;184(4):193–7. https://doi.org/10.1007/s00066-008-1810-x . (PMID: 18398583).
doi: 10.1007/s00066-008-1810-x
pubmed: 18398583
Casey DL, Alektiar KM, Gerber NK, Wolden SL. Whole lung irradiation for adults with pulmonary metastases from Ewing sarcoma. Int J Radiat Oncol Biol Phys. 2014;89(5):1069–75. https://doi.org/10.1016/j.ijrobp.2014.04.036 . (Epub 2014 Jul 8 PMID: 25035210).
doi: 10.1016/j.ijrobp.2014.04.036
pubmed: 25035210
Liu AK, Stinauer M, Albano E, Greffe B, Tello T, Maloney K. Local control of metastatic sites with radiation therapy in metastatic Ewing sarcoma and rhabdomyosarcoma. Pediatr Blood Cancer. 2011;57(1):169–71. https://doi.org/10.1002/pbc.23063 . (Epub 2011 Mar 24 PMID: 21557463).
doi: 10.1002/pbc.23063
pubmed: 21557463
Bosma SE, Ayua Fiocco M, Gelderblom H, Dijkstra PDS. Prognostic factors for survival in Ewing sarcoma: a systematic review. Surg Oncol. 2018;27(4):603–10.
doi: 10.1016/j.suronc.2018.07.016
pubmed: 30449479
Barker LM, Pendergrass TW, Sanders JE, Hawkins DS. Survival after recurrence of Ewing’s sarcoma family of tumors. J Clin Oncol. 2005;23(19):4354–62. https://doi.org/10.1200/JCO.2005.05.105 . (Epub 2005 Mar 21 PMID: 15781881).
doi: 10.1200/JCO.2005.05.105
pubmed: 15781881
Bacci G, Longhi A, Ferrari S, Mercuri M, Barbieri E, Bertoni F, Bacchini P, Picci P. Pattern of relapse in 290 patients with nonmetastatic Ewing’s sarcoma family tumors treated at a single institution with adjuvant and neoadjuvant chemotherapy between 1972 and 1999. Eur J Surg Oncol. 2006;32(9):974–9. https://doi.org/10.1016/j.ejso.2006.01.023 . (Epub 2006 Apr 18 PMID: 16621429).
doi: 10.1016/j.ejso.2006.01.023
pubmed: 16621429
Ferrari S, et al. Response to high-dose ifosfamide in patients with advanced/recurrent Ewing sarcoma. Pediatr Blood Cancer. 2009;52(5):581–4.
doi: 10.1002/pbc.21917
pubmed: 19142994
Rapkin L, Qayed M, Brill P, Martin M, Clark D, George BA, Olson TA, Wasilewski-Masker K, Alazraki A, Katzenstein HM. Gemcitabine and docetaxel (GEMDOX) for the treatment of relapsed and refractory pediatric sarcomas. Pediatr Blood Cancer. 2012;59(5):854–8. https://doi.org/10.1002/pbc.24101 . (Epub 2012 Feb 2 PMID: 22302783).
doi: 10.1002/pbc.24101
pubmed: 22302783
Farhat R, Raad R, Khoury NJ, Feghaly J, Eid T, Muwakkit S, Abboud M, El-Solh H, Saab R. Cyclophosphamide and topotecan as first-line salvage therapy in patients with relapsed Ewing sarcoma at a single institution. J Pediatr Hematol Oncol. 2013;35(5):356–60. https://doi.org/10.1097/MPH.0b013e318270a343 . (PMID: 23042020).
doi: 10.1097/MPH.0b013e318270a343
pubmed: 23042020
McCabe MG, et al. Results of the first interim assessment of rEECur, an international randomised controlled trial of chemotherapy for the treatment of recurrent and primary refractory Ewing sarcoma. J Clin Oncol. 2019;37(15_suppl):11007–11.
doi: 10.1200/JCO.2019.37.15_suppl.11007
McCabe MG, Kirton L, Khan M, Fenwick N, et al. Results of the second interim assessment of rEECur, an international randomised controlled trial of chemotherapy for the treatment of recurrent and primary refractory Ewing sarcoma (RR-ES). J Clin Oncol. 2020;38(15 suppl):11502.
doi: 10.1200/JCO.2020.38.15_suppl.11502
Rasper M, Jabar S, Ranft A, Jürgens H, Amler S, Dirksen U. The value of high-dose chemotherapy in patients with first relapsed Ewing sarcoma. Pediatr Blood Cancer. 2014;61(8):1382–6. https://doi.org/10.1002/pbc.25042 . (Epub 2014 Apr 11 PMID: 24729428).
doi: 10.1002/pbc.25042
pubmed: 24729428
Italiano A, Mir O, Mathoulin-Pelissier S, Penel N, Piperno-Neumann S, et al. Cabozantinib in patients with advanced Ewing sarcoma or osteosarcoma (CABONE): a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2020;21(3):446–55. https://doi.org/10.1016/S1470-2045(19)30825-3 . (Epub 2020 Feb 17. PMID: 32078813; PMCID: PMC8763616).
doi: 10.1016/S1470-2045(19)30825-3
pubmed: 32078813
pmcid: 8763616
Duffaud F, Blay JY, Le Cesne A, Chevreau C, Boudou-Rouquette P, Kalbacher E, Penel N, Perrin C, Laurence V, Bompas E, Saada-Bouzid E, Delcambre C, Bertucci F, Cancel M, Schiffler C, Monard L, Bouvier C, Vidal V, Gaspar N, Chabaud S. Regorafenib in patients with advanced Ewing sarcoma: results of a non-comparative, randomised, double-blind, placebo-controlled, multicentre Phase II study. Br J Cancer. 2023;129(12):1940–8. https://doi.org/10.1038/s41416-023-02413-9 . (Epub 2023 Nov 1. PMID: 37914801; PMCID: PMC10703915).
doi: 10.1038/s41416-023-02413-9
pubmed: 37914801
Grohar P, Ballman KV, Heise R, Glod J, Wedekind MF, Mascarenhas L, Gedminas JM, DuBois SG, Maki RG, Crompton BD, Hayashi M, Peer CJ, Figg WD, Lindenberg ML, Gonzalez EM, Bagatell R, Laetsch TW, Widemann BC, Reinke DK, Chugh R. SARC037: Results of phase I study of trabectedin given as a 1-hour (h) infusion in combination with low dose irinotecan in relapsed/refractory Ewing sarcoma (ES). J Clin Oncol. 2023;41(16_suppl):11519.
doi: 10.1200/JCO.2023.41.16_suppl.11519
Heinemann M, Ranft A, Langer T, Jürgens H, Kreyer J, Vieth V, et al. Recurrence of Ewing sarcoma: Is detection by imaging follow-up protocol associated with survival advantage? Pediatr Blood Cancer. 2018;65(7):1–7.
doi: 10.1002/pbc.27011
Liu F, Zhang Q, Zhu D, Liu F, Li Z, Li J, Wang B, Zhou D, Dong J. Performance of positron emission tomography and positron emission tomography/computed tomography using fluorine-18-fluorodeoxyglucose for the diagnosis, staging, and recurrence assessment of bone sarcoma: a systematic review and meta-analysis. Medicine (Baltimore). 2015;94(36): e1462. https://doi.org/10.1097/MD.0000000000001462 . (Erratum in: Medicine (Baltimore). 2016 Jan;95(2):e187a. Liu, Fengxia [Added]. Erratum in: Medicine (Baltimore). 2016 Jan 15;95(2):e187a. PMID: 26356700; PMCID: PMC4616630).
doi: 10.1097/MD.0000000000001462
pubmed: 26356700
Chang KJ, Kong CB, Cho WH, Jeon DG, Lee SY, Lim I, Lim SM. Usefulness of increased 18F- FDG uptake for detecting local recurrence in patients with extremity osteosarcoma treated with surgical resection and endoprosthetic replacement. Skeletal Radiol. 2015;44(4):529–37. https://doi.org/10.1007/s00256-014-2063-7 . (Epub 2014 Nov 29 PMID: 25431093).
doi: 10.1007/s00256-014-2063-7
pubmed: 25431093
Cipriano CA, Jang E, Tyler W. Sarcoma surveillance: a review of current evidence and guidelines. J Am Acad Orthop Surg. 2020;28(4):145–56.
doi: 10.5435/JAAOS-D-19-00002
pubmed: 31651565
Goedhart LM, Leithner A, Ploegmakers JJW, Jutte PC. Follow-Up in Bone Sarcoma Care: A Cross-Sectional European Study. Sarcoma. 2020;2020:2040347. https://doi.org/10.1155/2020/2040347 . PMID: 32675939; PMCID: PMC7350160.